Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
enGene Holdings ( (ENGN) ) has shared an update.
enGene Holdings Inc. announced its participation in several investor conferences in September, including the Wells Fargo Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, and Morgan Stanley Annual Global Healthcare Conference. This participation highlights enGene’s ongoing efforts to engage with investors and stakeholders, potentially impacting its industry positioning and stakeholder relations.
The most recent analyst rating on (ENGN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for mucosal tissues and other organs. Their lead program, detalimogene voraplasmid, targets Non-Muscle Invasive Bladder Cancer and is being evaluated in a Phase 2 trial for high-risk patients.
Average Trading Volume: 83,740
Technical Sentiment Signal: Hold
Current Market Cap: $222.8M
Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.